Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Esperion Therapeutics, Inc. (ESPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 SC 13G Two Seas Capital LP reports a 7.4% stake in Esperion Therapeutics, Inc.
08/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/18/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/01/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
07/19/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 SC 13G/A BlackRock Inc. reports a 4.9% stake in ESPERION THERAPEUTICS INC
05/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Esperion Reports First Quarter 2023 Financial Results – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y&#59; New to Brand Prescriptions Grew 56% Q/Q –"
05/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37"
04/19/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/05/2023 SC 13G Point72 Asset Management, L.P. reports a 5% stake in Esperion Therapeutics, Inc.
04/03/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/27/2023 8-K Quarterly results
03/22/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Opinion of Goodwin Procter LLP",
"Form of Securities Purchase Agreement",
"Form of Warrant Amendment Agreement",
"Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules",
"Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules"
03/22/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/21/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/17/2023 144 Form 144 - Report of proposed sale of securities:
03/15/2023 8-K Other Events  Interactive Data
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/07/2023 144 Form 144 - Report of proposed sale of securities:
03/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Landmark CLEAR Outcomes Study Demonstrates NEXLETOL Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin"
02/14/2023 SC 13G/A CVI Investments, Inc. reports a 6.9% stake in Esperion Therapeutics, Inc.
02/10/2023 SC 13G/A WASATCH ADVISORS INC reports a 12.8% stake in Esperion Therapeutics, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 5.8% stake in Esperion Therapeutics Inc.
02/07/2023 SC 13G BlackRock Inc. reports a 7.5% stake in ESPERION THERAPEUTICS INC
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy